NYSE$ABT

Abbott Laboratories · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Abbott's Q2 2021 earnings were announced, demonstrating strong growth across the portfolio.

Abbott's Q2 2021 results revealed a robust performance, with worldwide sales reaching $10.2 billion, a 39.5% increase on a reported basis and 35.0% organically. Excluding COVID-19 testing-related sales, sales grew 11.3% organically compared to pre-pandemic levels in Q2 2019. The company's EPS guidance for 2021 is $2.75 to $2.95.

  • Worldwide sales increased by 39.5% on a reported basis and 35.0% on an organic basis.
  • Excluding COVID-19 testing-related sales, worldwide sales increased 11.3% organically compared to pre-pandemic levels in Q2 2019.
  • Global COVID-19 testing-related sales were $1.3 billion.
  • FreeStyle Libre® sales were $904 million, representing 52.5% reported sales growth and 42.9% organic sales growth.

Headline financials

Total Revenue

$10.2B

Previous: $7.33B+39.5%
EPS (adj)

$1.17

Previous: $0.57+105.3%
Capital Expenditures

-$810M

Previous: -$1B+19.2%
Free Cash Flow

$379M

Previous: -$465M+181.5%
Net Income

$1.19B

Previous: $537M+121.4%
Operating Income

$1.39B

Previous: $672M+107.1%
Gross Profit

$5.28B

Previous: $4.07B+29.8%
Cash & Equivalents

$8.66B

Previous: $4.76B+81.8%
Total Assets

$73.3B

Previous: $68.8B+6.5%
Stock-Based Comp

$132M

Previous: $115M+14.8%

Revenue & EPS history

Abbott · Revenue · Quarterly

$10.2B

Q2 2021+39.5%vs Q2 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Abbott · $6.7B total across 2 segments · Q3 2023

  • Medical Devices
    $4.25B+17.5%
  • Diagnostics
    $2.45B-33.3%

Forward guidance

Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $2.75 to $2.95. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for full-year 2021.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+0.6%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+1.1%

Avg return

30 days after

61%

45 / 74 earnings

Positive

+10.3%

Q3 2013

Best reaction

-9.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.2%-8.7%-16.8%
Q4 2025-9.9%-10.3%-7.1%
Q3 2025-2.9%-2.8%-2.0%
Q2 2025-0.1%+1.4%+3.3%
Q1 2025+2.8%+2.9%+6.8%
Q4 2024+0.8%+10.8%+15.5%
Q3 2024+1.6%+0.8%-0.1%
Q2 2024-2.5%-0.7%+6.0%
Q1 2024-3.6%-2.0%-4.7%
Q4 2023-1.4%-0.5%+4.8%
Q3 2023+3.6%+4.0%+8.0%
Q2 2023+6.5%+5.3%-3.3%
Q1 2023+6.0%+6.0%+4.6%
Q4 2022-1.3%-2.4%-10.7%
Q3 2022-9.3%-6.4%-1.1%
Q2 2022+0.7%-1.3%+0.1%
Q1 2022+2.8%+0.0%-5.6%
Q4 2021-2.3%+3.4%-0.7%
Q3 2021+4.8%+6.1%+6.3%
Q2 2021+1.5%+0.7%+6.2%
Q1 2021-1.5%-1.0%-5.4%
Q4 2020+4.9%+6.8%+4.4%
Q3 2020+1.0%+0.6%+2.3%
Q2 2020+2.6%+1.5%+3.4%
Q1 2020+5.6%+3.4%-1.2%
Q4 2019+1.1%-0.2%-2.5%
Q3 2019+0.5%-0.4%+4.5%
Q2 2019+5.5%+5.9%+1.9%
Q1 2019-3.2%-2.4%-0.5%
Q4 2018-0.9%-3.4%+6.5%
Q3 2018-4.0%-3.4%+1.5%
Q2 2018+1.6%+0.6%+3.1%
Q1 2018+0.1%-1.6%+3.2%
Q4 2017+6.7%+6.9%+0.8%
Q3 2017+1.7%+1.9%+0.9%
Q2 2017+2.9%+2.8%-1.4%
Q1 2017+1.3%+1.6%-0.6%
Q4 2016+1.6%+1.6%+12.5%
Q3 2016-1.0%-1.8%-3.2%
Q2 2016+3.0%+3.9%+5.8%
Q1 2016+0.1%
Q4 2015-6.5%
Q3 2015+4.2%
Q2 2015+2.9%
Q1 2015+2.8%
Q4 2014+3.1%
Q3 2014+0.1%
Q2 2014+1.8%
Q1 2014+2.5%
Q4 2013-4.3%
Q3 2013+10.3%
Q2 2013+0.0%
Q1 2013+1.3%
Q4 2012-0.3%
Q3 2012-7.6%
Q2 2012-1.0%
Q1 2012-1.5%
Q4 2011-0.2%
Q3 2011-0.4%
Q2 2011-0.1%
Q1 2011+0.9%
Q1 2008+1.4%
Q4 2010+1.4%
Q3 2010-0.8%
Q2 2010+0.7%
Q1 2009-1.4%
Q1 2010+0.9%
Q4 2007-1.1%
Q4 2009-1.1%
Q3 2008+1.4%
Q3 2009+1.4%
Q2 2009+2.1%
Q4 2008+2.1%
Q2 2008+2.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro